A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Clinical trial NCT05428969 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05428969
Sponsor: Faron Pharmaceuticals Ltd
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Myelodysplastic Syndromes Relapsed/Refractory AML

Start date: 2022-06-02
Primary completion: 2027-03-01
Enrollment: 181

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.